Navigation Links
Isotechnika Announces Interim Three Month Data from Phase 2b Kidney,Transplant Trial

ts to develop and commercialize ISA247 for all transplant indications.

On September 30, 2005, Isotechnika Inc. entered into an exclusive worldwide licensing agreement with Atrium Medical Corporation for the use of ISA247 and TAFA93 specifically with drug eluting devices for the non-systemic treatment of vascular, cardiovascular, target vessel and tissue disorders.

Isotechnika Inc. and Cellgate Inc. signed an option agreement on April 25, 2006, granting Isotechnika the option to obtain an exclusive license to develop and commercialize conjugates consisting of Cellgate's patented transporter technology for the topical delivery of ISA247 in patients suffering from mild to moderate psoriasis.

On May 25, 2006, Isotechnika Inc. signed an agreement with Lux Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences worldwide rights to develop and commercialize Isotechnika's lead drug, ISA247 for the treatment and prophylaxis of all ophthalmic diseases.

Forward-Looking Statements

--------------------------

This press release may contain forward-looking statements. Forward looking statements, including the Company's belief as to the potential of its products, the Company's expectations regarding the issuance of additional patents and the Company's ability to protect its intellectual property, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the ability to economically manufacture its products, the potential of its products, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize its products, the ability of the Company to defend its patents from infringement by third parties, and the risk that the Company's patent
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Isotechnikas Lead Drug, ISA247, To Be Highlighted at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
2. Isotechnikas independent data monitoring committee conducts review of phase 2b kidney transplant trial
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:9/17/2014)...   MedeAnalytics today unveils Revenue Integrity, ... visibility to a provider,s "mid-cycle" to optimize revenue ... Powered by the industry,s leading big data platform, ... between patient access and the business office where ... revenue capture, minimize audit risk and prepare providers ...
(Date:9/17/2014)... --  myMatrixx, a pharmacy and ancillary medical benefit manager for workers, ... has awarded myMatrixx with a "Best Places to Work ... row. Best Places to Work is ... Best Companies Group.  The competition, which involves months of ... insurance industry companies with at least 25 employees in ...
(Date:9/17/2014)... MADISON, Tenn. , Sept. 17, 2014 ... be; these infections are not only uncomfortable, they,re often ... best-laid social plans. pH-D Feminine Health Support ( http://ph-defense.com ... vaginal health. It is an all-natural, homeopathic product. ... the most common symptoms of vaginal infection. In many ...
Breaking Medicine Technology:MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3myMatrixx Honored with "Best Places to Work in Insurance" Award 2New Product from Vireo Systems: pH-D Feminine Health Support 2
... FRANCISCO, Calif., Aug. 25, 2011 Rigel Pharmaceuticals, Inc. ... M. Gower, chairman and chief executive officer, and Ryan ... Rigel, will present at two separate investor conferences in ... Healthcare Conference 2011Date: Thursday, September 8th at 10:20 a.m. ...
... Nutrastar International Inc. (OTCBB: NUIN; "Nutrastar" or the "Company"), ... Chinese Medicine ("TCM") consumer products, today announced that its ... under which Nutrastar may repurchase up to US$5 million ... 12 months. Under the program, the ...
Cached Medicine Technology:Nutrastar Announces Adoption of Share Repurchase Program 2Nutrastar Announces Adoption of Share Repurchase Program 3
(Date:9/18/2014)... MD (PRWEB) September 18, 2014 A ... shaping system has been approved by the United States Food ... available for widespread purchase in the US, landmark dermatology center ... and only practices on the east coast to use this ... only practice in the Baltimore area to offer patients the ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Members ... online with participating network dentists at UnitedConcordia.com, thanks ... dental wellness company. , "Members can book an ... 'Schedule Now' button located on the Find a ... vice president of network operations at United Concordia. ...
(Date:9/18/2014)... 2014 MD Complete , the ... a prescription, announced today that SHAPE Magazine has named ... “Best Peel” in its annual Beauty Awards. The issue ... beauty products as tested by SHAPE’s expert team. , ... results. Among the thousands of beauty products launched every ...
(Date:9/18/2014)... 2014 One Week Kitchens will have their ... Fair beginning this Saturday. Their display will be inside the ... of the products and design services that are offered at ... for fair-goers to see. This display won ‘Most Beautiful Display’ ... year and really is something to see. , The ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Each year, ... of activities that coincide with National Health IT (NHIT) ... (IT/IS) professionals. To help Norman Regional show its gratitude, ... for hospitals , is contributing giveaway items to support ... a prize drawing and offering free lunches, Norman Regional ...
Breaking Medicine News(10 mins):Health News:New FDA-Approved UltraShape Body Contouring Procedure Comes to Maryland Laser Skin and Vein 2Health News:United Concordia Offers Real-time Online Scheduling for their Members, Through LocalMed 2Health News:United Concordia Offers Real-time Online Scheduling for their Members, Through LocalMed 3Health News:MD Complete Wins Shape Beauty Award for Best Peel 2Health News:One Week Kitchens Taking Display to Bloomsburg Fair 2Health News:Access Helps Norman Regional Hospital Celebrate Its Staff During National Health IT Week 2014 2
... Technologies, Inc. (Nasdaq: EFJI ) today announced its ... revenues decreased $11.5 million, or 34%, to $22.4 million for ... for the same period in 2008. This anticipated quarterly decline ... in revenues associated with the FCC re-banding effort. "While our ...
... May 6 NeoStem, Inc. (NYSE Amex: ... and long-term storage of adult stem cells for future ... proprietary stem cell technology of Vincent C. Giampapa, ... first licensed in February 2009.The newest adult stem cell ...
... Pharmaceuticals Corp., a developer and manufacturer of medical products that ... the first quarter of 2009. , For the quarter ended ... million, or $0.06 cents per share, on revenues of $4.1 ... or $0.12 cents per share, on revenues of $5.2 million ...
... EntreMed, Inc. (Nasdaq: ENMD ), a ... cancer and inflammatory diseases, today reported financial results for ... http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ) , The Company ... approximately ($3.5 million), or ($0.04) per share, compared with ...
... cancers at Women,s Dermatologic Society outreach at Family Circle ... safety and skin health, South Carolina physicians representing the ... cancer screenings and education for fans enjoying the Family ... day of outreach, local dermatologists referred 38% of the ...
... May 6 Micromet, Inc. (Nasdaq: MITI ... the treatment of cancer, inflammation and autoimmune diseases, today ... March 31, 2009.In the first quarter of 2009, Micromet ... progress in the clinic and in corporate development. ...
Cached Medicine News:Health News:EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results 2Health News:EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results 3Health News:EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results 4Health News:EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results 5Health News:EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results 6Health News:NeoStem Files Patent Application for Cosmetic Stem Cell Face Lift Technology and Expands Stem Cell Collection Network into New Jersey 2Health News:NeoStem Files Patent Application for Cosmetic Stem Cell Face Lift Technology and Expands Stem Cell Collection Network into New Jersey 3Health News:NUCRYST announces 2009 first quarter financial results 2Health News:NUCRYST announces 2009 first quarter financial results 3Health News:NUCRYST announces 2009 first quarter financial results 4Health News:NUCRYST announces 2009 first quarter financial results 5Health News:NUCRYST announces 2009 first quarter financial results 6Health News:NUCRYST announces 2009 first quarter financial results 7Health News:EntreMed Reports First Quarter 2009 Financial Results 2Health News:EntreMed Reports First Quarter 2009 Financial Results 3Health News:South Carolina Dermatologists Win Tennis Fans' Attention With Free Skin Cancer Checks and Sun Safety Tips 2Health News:South Carolina Dermatologists Win Tennis Fans' Attention With Free Skin Cancer Checks and Sun Safety Tips 3Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 2Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 3Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 4Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 5Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 6Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 7Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 8Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 9
... The Leica TP1020 product family are ... a perfect combination of approved technology with ... processing and maximum safety for tissues at ... engineering design based on proven precision mechanics ...
The HMP300 Histo Pro delivers all the features and benefits that conventional tissue processing have to offer....
... electronic, motorized rotary microtomes ... applications of paraffin, semi-thin ... specimens in clinical, research, ... instruments display extra-ordinary ergonomic ...
... RM2235 is a robust rotary microtome ... biological specimens embedded in paraffin. The ... micrometer feed system ensures premium quality ... sectioning harder tissues. The RM2235 is ...
Medicine Products: